With PhII fail, Redx Pharma scraps monotherapy biliary cancer development for lead program
UK biotech Redx Pharma’s lead drug has failed a Phase II study for biliary tract cancer, and the results are “not sufficient” to continue development as a monotherapy in that indication, the company announced Wednesday.
RXC004, a porcupine inhibitor being developed to treat Wnt-ligand dependent cancers in patients whose disease progressed after other treatments, failed to hit the primary endpoint — progression-free survival at six months.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.